Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | ALK tyrosine kinase receptor | ||
Ligand | BDBM50396270 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | ChEMBL_863887 (CHEMBL2176371) | ||
IC50 | 2±n/a nM | ||
Citation | Lewis, RT; Bode, CM; Choquette, DM; Potashman, M; Romero, K; Stellwagen, JC; Teffera, Y; Moore, E; Whittington, DA; Chen, H; Epstein, LF; Emkey, R; Andrews, PS; Yu, VL; Saffran, DC; Xu, M; Drew, A; Merkel, P; Szilvassy, S; Brake, RL The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer. J Med Chem55:6523-40 (2012) [PubMed] Article | ||
More Info.: | Get all data from this article, Assay Method | ||
ALK tyrosine kinase receptor | |||
Name: | ALK tyrosine kinase receptor | ||
Synonyms: | ALK | ALK tyrosine kinase receptor (ALK) | ALK_HUMAN | Anaplastic lymphoma kinase | CD_antigen: CD246 | ||
Type: | Protein | ||
Mol. Mass.: | 176453.10 | ||
Organism: | Homo sapiens (Human) | ||
Description: | Q9UM73 | ||
Residue: | 1620 | ||
Sequence: |
| ||
BDBM50396270 | |||
n/a | |||
Name | BDBM50396270 | ||
Synonyms: | CHEMBL2172319 | ||
Type | Small organic molecule | ||
Emp. Form. | C33H43F2N5O3 | ||
Mol. Mass. | 595.723 | ||
SMILES | CC(C)NC(=O)[C@H]1CC[C@H](CC1)n1c(NC(=O)c2ccc(F)c(F)c2)nc2ccc(CN3CCC(CC3)C(C)(C)O)cc12 |r,wU:9.12,6.5,(46.48,-42.35,;44.97,-42.04,;44.49,-40.57,;43.95,-43.18,;42.44,-42.87,;41.41,-44.01,;41.96,-41.4,;40.45,-41.08,;39.98,-39.63,;41.01,-38.48,;42.51,-38.79,;42.99,-40.25,;40.52,-37.02,;41.43,-35.76,;42.97,-35.75,;43.73,-34.42,;42.95,-33.09,;45.26,-34.4,;46.02,-33.07,;47.56,-33.05,;48.34,-34.39,;49.88,-34.38,;47.58,-35.72,;48.36,-37.05,;46.04,-35.73,;40.51,-34.51,;39.04,-35,;37.7,-34.24,;36.37,-35.01,;36.37,-36.55,;35.04,-37.32,;33.7,-36.55,;33.71,-35.01,;32.39,-34.24,;31.05,-35,;31.05,-36.54,;32.38,-37.32,;29.71,-34.22,;28.94,-32.89,;30.48,-32.88,;28.38,-34.99,;37.7,-37.32,;39.04,-36.55,)| | ||
Structure |